Industry Corner Live With Biolinq Co-Founder Jared Tangney

In this IEEE Pulse Industry Corner Live interview, Editor-in-Chief Chad Andresen speaks with Jared Tangney, Ph.D., co-founder and Chief Technology Officer of Biolinq, about the decade-long journey from university research to FDA-bound product. Biolinq has developed a next-generation continuous glucose monitoring (CGM) platform that leverages silicon-based micro-needle arrays to measure biomarkers painlessly within the upper layers of the skin. Tangney discusses the company's translation from NIH-funded feasibility studies to large-scale semiconductor manufacturing, the role of non-invasive, multi-analyte sensing for metabolic health, and the challenges of balancing innovation speed with regulatory rigor. He also outlines Biolinq's expansion beyond glucose toward lactate, cortisol, and phenylalanine monitoring, enabling broader applications in wellness, sports performance, and cognitive resilience. This conversation highlights the perseverance required to commercialize disruptive biosensing technology and underscores the growing convergence of wearable electronics, biotechnology, and AI-driven health data in reshaping personalized medicine.